Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases

Cancer Biology and Therapy

Volumn 14, Issue 5, 2013, Pages 417-427

  Nangia Makker, Pratima ^a   Raz, Tirza ^a   Tait, Larry ^a   Shekhar, Malathy P V ^a   Li, Hong ^b   Balan, Vitaly ^a   Makker, Hemanckur ^c   Fridman, Rafael ^a   Maddipati, Krishnarao ^a,c   Raz, Avraham ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHONGQING UNIVERSITY OF EDUCATION   (China)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; MMP; Ocimum gratissimum; Tumor progression

Indexed keywords

GALECTIN 3; GELATIN; GELATINASE A; GELATINASE B; OCIMUM GRATISSIMUM EXTRACT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; INTRADUCTAL CARCINOMA; MOUSE; NONHUMAN; OCIMUM GRATISSIMUM; TUMOR INVASION;

BREAST CANCER; MMP; OCIMUM GRATISSIMUM; TUMOR PROGRESSION;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MICE, NUDE; OCIMUM; PLANT EXTRACTS; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877870993     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.23762     Document Type: Article

References (50)

1. Gupta SK, Prakash J, Srivastava S. Validation of traditional claim of Tulsi, Ocimum sanctum Linn. as a medicinal plant. Indian J Exp Biol 2002; 40:765-73; PMID:12597545.
2. Nangia-Makker P, Tait L, Shekhar MP, Palomino E, Hogan V, Piechocki MP, et al. Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum. Int J Cancer 2007; 121:884-94; PMID:17437270; http://dx.doi.org/10.1002/ijc.22733.
3. Chen HM, Lee MJ, Kuo CY, Tsai PL, Liu JY, Kao SH. Ocimum gratissimum Aqueous Extract Induces Apoptotic Signalling in Lung Adenocarcinoma Cell A549. Evid Based Complement Alternat Med 2011; 2011; PMID:20953389; http://dx.doi.org/10.1155/2011/739093.
4. Kim SC, Magesh V, Jeong SJ, Lee HJ, Ahn KS, Lee HJ, et al. Ethanol extract of Ocimum sanctum exerts anti-metastatic activity through inactivation of matrix metalloproteinase-9 and enhancement of antioxidant enzymes. Food Chem Toxicol 2010; 48:1478-82; PMID:20233602; http://dx.doi.org/10.1016/j.fct.2010. 03.014.
5. Sharma M, Agrawal SK, Sharma PR, Chadha BS, Khosla MK, Saxena AK. Cytotoxic and apoptotic activity of essential oil from Ocimumviride towards COLO 205 cells. Food Chem Toxicol 2010; 48:336-44; PMID:19852999; http://dx.doi.org/10.1016/j.fct.2009.10.021.
6. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141:52-67; PMID:20371345; http://dx.doi.org/10.1016/j.cell.2010.03.015.
7. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011; 41:271-90; PMID:20640864; http://dx.doi.org/10.1007/s00726-010-0689-x.
8. Hatfield KJ, Reikvam H, Bruserud O. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr Med Chem 2010; 17:4448-61; PMID:21062258; http://dx.doi.org/10.2174/ 092986710794183033.
9. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27:5287-97; PMID:19738110; http://dx.doi.org/10.1200/JCO.2009.23.5556.
10. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007; 42:113-85; PMID:17562450; http://dx.doi.org/10.1080/10409230701340019.
11. Rodríguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 2010; 1803:39-54; PMID:19800373; http://dx.doi.org/10.1016/j.bbamcr.2009.09.015.
12. Alexander CM, Hansell EJ, Behrendtsen O, Flannery ML, Kishnani NS, Hawkes SP, et al. Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. Development 1996; 122:1723-36; PMID:8674412.
13. Currie JC, Fortier S, Sina A, Galipeau J, Cao J, Annabi B. MT1-MMP down-regulates the glucose 6-phosphate transporter expression in marrow stromal cells: a molecular link between pro-MMP-2 activation, chemotaxis, and cell survival. J Biol Chem 2007; 282:8142-9; PMID:17229722; http://dx.doi.org/10. 1074/jbc.M610894200.
14. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-74; PMID:11990853; http://dx.doi.org/10.1038/nrc745.
15. Deryugina EI, Quigley JP. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta 2010; 1803:103-20; PMID:19800930; http://dx.doi.org/10. 1016/j.bbamcr.2009.09.017.
16. Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG. Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol 2012; 181:1895-9; PMID:23063657; http://dx.doi.org/10.1016/j.ajpath.2012. 08.044.
17. Rydlova M, Holubec L Jr., Ludvikova M Jr., Kalfert D, Franekova J, Povysil C, et al. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 2008; 28(2B):1389-97; PMID:18505085.
18. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005; 87:287-97; PMID:15781315; http://dx.doi.org/10.1016/j.biochi. 2005.01.014.
19. Yu XF, Han ZC. Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. Histol Histopathol 2006; 21:519-31; PMID:16493582.
20. Polette M, Gilbert N, Stas I, Nawrocki B, Nöel A, Remacle A, et al. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch 1994; 424:641-5; PMID:8055158; http://dx.doi.org/10.1007/ BF01069745.
21. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2:737-44; PMID:11025665; http://dx.doi.org/10.1038/35036374.
22. Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005; 1755:37-69; PMID:15907591.
23. Hahn-Dantona E, Ruiz JF, Bornstein P, Strickland DK. The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism. J Biol Chem 2001; 276:15498-503; PMID:11279011; http://dx.doi.org/10.1074/jbc.M100121200.
24. Van den Steen PE, Van Aelst I, Hvidberg V, Piccard H, Fiten P, Jacobsen C, et al. The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J Biol Chem 2006; 281:18626-37; PMID:16672230; http://dx.doi.org/10.1074/jbc. M512308200.
25. Yang Z, Strickland DK, Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 2001; 276:8403-8; PMID:11113133; http://dx.doi.org/10.1074/jbc. M008925200.
26. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012; 1825:29-36; PMID:22020293.
27. Overall CM. Dilating the degradome: matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter. Biochem J 2004; 383:e5-7; PMID:15508185; http://dx.doi.org/10.1042/BJ20041433.
28. Balbín M, Fueyo A, Tester AM, Pendás AM, Pitiot AS, Astudillo A, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003; 35:252-7; PMID:14517555; http://dx.doi.org/10.1038/ng1249.
29. Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, et al. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 2010; 127:2530-41; PMID:20162566; http://dx.doi.org/10.1002/ijc. 25254.
30. Nangia-Makker P, Raz T, Tait L, Hogan V, Fridman R, Raz A. Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res 2007; 67:11760-8; PMID:18089806; http://dx.doi.org/10.1158/0008-5472.CAN-07-3233.
31. Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, et al. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994; 33:14109-14; PMID:7947821; http://dx.doi.org/10.1021/bi00251a020.
32. Nangia-Makker P, Raz T, Tait L, Hogan V, Fridman R, Raz A. Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res 2007; 67:11760-8; PMID:18089806; http://dx.doi.org/10.1158/0008-5472.CAN-07-3233.
33. Fisher ER, Land SR, Saad RS, Fisher B, Wickerham DL, Wang M, et al. Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. Am J Clin Pathol 2007; 128:86-91; PMID:17580274; http://dx.doi.org/10.1309/WH9LA543NR76Y29J.
34. Yang M, Moriya T, Oguma M, De La Cruz C, Endoh M, Ishida T, et al. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases. Pathol Int 2003; 53:422-8; PMID:12828606; http://dx.doi.org/10.1046/j.1440-1827.2003.01498.x.
35. Shekhar MP, Tait L, Pauley RJ, Wu GS, Santner SJ, Nangia-Makker P, et al. Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death. Cancer Biol Ther 2008; 7:1774-82; PMID:18787417; http://dx.doi.org/10.4161/cbt. 7.11.6781.
36. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 2000; 92:1185-6; PMID:10904098; http://dx.doi.org/10.1093/jnci/92.14.1185A.
37. Tait LR, Pauley RJ, Santner SJ, Heppner GH, Heng HH, Rak JW, et al. Dynamic stromal-epithelial interactions during progression of MCF10DCIS. com xenografts. Int J Cancer 2007; 120:2127-34; PMID:17266026; http://dx.doi.org/10. 1002/ijc.22572.
38. Prakash P, Gupta N. Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: a short review. Indian J Physiol Pharmacol 2005; 49:125-31; PMID:16170979.
39. Dumic J, Dabelic S, Flögel M. Galectin-3: an openended story. Biochim Biophys Acta 2006; 1760:616-35; PMID:16478649; http://dx.doi.org/10. 1016/j.bbagen.2005.12.020.
40. Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, Pienta KJ, et al. Regulation of prostate cancer progression by galectin-3. Am J Pathol 2009; 174:1515-23; PMID:19286570; http://dx.doi.org/10.2353/ajpath.2009.080816.
41. Boonrao M, Yodkeeree S, Ampasavate C, Anuchapreeda S, Limtrakul P. The inhibitory effect of turmeric curcuminoids on matrix metalloproteinase-3 secretion in human invasive breast carcinoma cells. Arch Pharm Res 2010; 33:989-98; PMID:20661707; http://dx.doi.org/10.1007/s12272-010-0703-6.
42. Weng CJ, Wu CF, Huang HW, Ho CT, Yen GC. Anti-invasion effects of 6-shogaol and 6-gingerol, two active components in ginger, on human hepatocarcinoma cells. Mol Nutr Food Res 2010; 54:1618-27; PMID:20521273; http://dx.doi.org/10.1002/mnfr.201000108.
43. Qin S, Alcorn JF, Craigo JK, Tjoeng C, Tarwater PM, Kolls JK, et al. Epigallocatechin-3-gallate reduces airway inflammation in mice through binding to proinflammatory chemokines and inhibiting inflammatory cell recruitment. J Immunol 2011; 186:3693-700; PMID:21307292; http://dx.doi.org/10.4049/jimmunol. 1002876.
44. Deng YT, Lin JK. EGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrest. J Agric Food Chem 2011; 59:13318-27; PMID:22082235; http://dx.doi.org/10.1021/jf204149c.
45. Donà M, Dell'Aica I, Pezzato E, Sartor L, Calabrese F, Della Barbera M, et al. Hyperforin inhibits cancer invasion and metastasis. Cancer Res 2004; 64:6225-32; PMID:15342408; http://dx.doi.org/10.1158/0008-5472.CAN-04- 0280.
46. Chiu CC, Huang CY, Chen TY, Kao SH, Liu JY, Wang YW, et al. Beneficial Effects of Ocimum gratissimum Aqueous Extract on Rats with CCl(4)-Induced Acute Liver Injury. Evid Based Complement Alternat Med 2012; 2012:736752; PMID:22792126; http://dx.doi.org/10.1155/2012/736752.
47. Shekhar MP, Werdell J, Tait L. Interaction with endothelial cells is a prerequisite for branching ductalalveolar morphogenesis and hyperplasia of preneoplastic human breast epithelial cells: regulation by estrogen. Cancer Res 2000; 60:439-49; PMID:10667599.
48. Ikejiri M, Bernardo MM, Bonfil RD, Toth M, Chang M, Fridman R, et al. Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem 2005; 280:33992-4002; PMID:16046398; http://dx.doi.org/10.1074/jbc.M504303200.
49. Olson MW, Bernardo MM, Pietila M, Gervasi DC, Toth M, Kotra LP, et al. Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem 2000; 275:2661-8; PMID:10644727; http://dx.doi.org/10.1074/jbc.275.4.2661.
50. Mook OR, Van Overbeek C, Ackema EG, Van Maldegem F, Frederiks WM. In situ localization of gelatinolytic activity in the extracellular matrix of metastases of colon cancer in rat liver using quenched fluorogenic DQ-gelatin. J Histochem Cytochem 2003; 51:821-9; PMID:12754293; http://dx.doi.org/10.1177/ 002215540305100613.